Structure-Activity Relationships of Synthetic Cathinones

  • Richard A. GlennonEmail author
  • Małgorzata Dukat
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 32)


Until recently, there was rather little interest in the structure-activity relationships (SARs) of cathinone analogs because so few agents were available and because they represented a relatively minor drug abuse problem. Most of the early SAR was formulated on the basis of behavioral (e.g., locomotor and drug discrimination) studies using rodents. With the emergence on the clandestine market in the last few years of a large number of new cathinone analogs, termed “synthetic cathinones”, and the realization that they likely act at dopamine, norepinephrine, and/or serotonin transporters as releasing agents (i.e., as substrates) or reuptake inhibitors (i.e., as transport blockers), it has now become possible to better examine their SAR and even their quantitative SAR (QSAR), in a more effective and systematic manner. An SAR picture is beginning to emerge, and key structural features, such as the nature of the terminal amine, the size of the α-substituent, stereochemistry, and the presence and position of aromatic substituents, are being found to impact action (i.e., as releasing agents or reuptake inhibitors) and transporter selectivity.


DAT Methcathinone Monoamine transporters NET QSAR SAR SERT 



Work from the authors’ laboratory was supported by US Public Health Services grants DA-01642 and DA-033930.


  1. 1.
    Glennon RA, Young R (2011) Drug discrimination: applications to medicinal chemistry and drug studies. Wiley, HobokenCrossRefGoogle Scholar
  2. 2.
    UNODC (2013) The challenge of new psychoactive substances. United Nations Office of Drugs and Crime, ViennaGoogle Scholar
  3. 3.
    EMCDDA (2015) European Drug Report. Trends and Developments. European Monitoring Centre for Drugs and Drug Addiction. LuxembourgGoogle Scholar
  4. 4.
    Glennon RA (2014) Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv Pharmacol 69:581–620CrossRefGoogle Scholar
  5. 5.
    Glennon RA, Showalter D (1981) The effect of cathinone and several related derivatives on locomotor activity. Res Commun Subst Abus 2:186–192Google Scholar
  6. 6.
    Glennon RA, Schechter MD, Rosecrans JA (1984) Discriminative stimulus properties of S(−)- and R(+)-cathinone, (+)-cathine and several structural modifications. Pharmacol Biochem Behav 21:1–3CrossRefGoogle Scholar
  7. 7.
    Glennon RA, Young R, Hauck AE, et al. (1984) Structure-activity studies on amphetamine analogs using drug discrimination methodology. Pharmacol Biochem Behav 21:895–901CrossRefGoogle Scholar
  8. 8.
    Goudie AJ, Atkinson J, West CR (1986) Discriminative properties of the psychostimulant dl-cathinone in a two lever operant task. Lack of evidence for dopaminergic mediation. Neuropharmacology 25:85–94CrossRefGoogle Scholar
  9. 9.
    Kalix P, Glennon RA (1986) Further evidence for an amphetamine-like mechanism of action of the alkaloid cathinone. Biochem Pharmacol 35:3015–3019CrossRefGoogle Scholar
  10. 10.
    Reith MEA, Blough BE, Hong WC, et al. (2015) Behavioral, biological, and chemical perspectives on a typical agents targeting the dopamine transporter. Drug Alcohol Depend 147:1–19CrossRefGoogle Scholar
  11. 11.
    Tang QY, Kolanos R, De Felice LJ, et al. (2015) Structural analysis of dopamine- and amphetamine-induced depolarization currents in the human dopamine transporter. ACS Chem Neurosci 6:551–558CrossRefGoogle Scholar
  12. 12.
    Dal Cason TA, Young R, Glennon RA (1997) Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol Biochem Behav 58:1109–1116CrossRefGoogle Scholar
  13. 13.
    Glennon RA, Yousif M, Naiman N, et al. (1987) Methcathinone: a new and potent amphetamine-like agent. Pharmacol Biochem Behav 26:547–551CrossRefGoogle Scholar
  14. 14.
    Bondareva TS, Young R, Glennon RA (2002) Central stimulants as discriminative stimuli: asymmetric generalization between (−)ephedrine and S(+)methamphetamine. Pharmacol Biochem Behav 74:157–162CrossRefGoogle Scholar
  15. 15.
    Young R, Glennon RA (1998) Discriminative stimulus properties of (−)ephedrine. Pharmacol Biochem Behav 60:771–775CrossRefGoogle Scholar
  16. 16.
    Foley KF, Cozzi NV (2003) Novel aminopropiophenones as potential antidepressants. Drug Dev Res 60:252–260CrossRefGoogle Scholar
  17. 17.
    Bondarev ML, Bondareva TS, Young R, et al. (2003) Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol 474:85–93CrossRefGoogle Scholar
  18. 18.
    Carroll FI, Blough BE, Abraham P, et al. (2009) Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem 52:6768–6781CrossRefGoogle Scholar
  19. 19.
    Markantonis SL, Kyroudis A, Beckett AH (1986) The stereoselective metabolism of dimethylpropion and monomethylpropion. Biochem Pharmacol 35:529–532CrossRefGoogle Scholar
  20. 20.
    Cozzi NV, Brandt SD, Daley PF, et al. (2013) Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur J Pharmacol 699:180–187CrossRefGoogle Scholar
  21. 21.
    Young R, Glennon RA (1993) Cocaine-stimulus generalization to two new designer drugs: methcathinone and 4-methylaminorex. Pharmacol Biochem Behav 45:229–231CrossRefGoogle Scholar
  22. 22.
    Kohut SJ, Fivel PA, Blough BE, et al. (2013) Effects of methcathinone and 3-Cl-methcathinone (PAL-434) in cocaine discrimination or self-administration in rhesus monkeys. Int J Neuropsychopharmacol 16:1985–1998CrossRefGoogle Scholar
  23. 23.
    Young R, Glennon RA (1998) Discriminative stimulus effects of S(−)-methcathinone (CAT): a potent stimulant drug of abuse. Psychopharmacology (Berl) 140:250–256CrossRefGoogle Scholar
  24. 24.
    Rothman RB, Vu N, Partilla JS, et al. (2003) In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective action as norepinephrine transporter substrates. J Pharmacol Exp Ther 307:138–145CrossRefGoogle Scholar
  25. 25.
    Young R, Glennon RA (2000) Stimulus effects of phenylpropanolamine optical isomers in (+)amphetamine-trained rats. Pharmacol Biochem Behav 66:489–494CrossRefGoogle Scholar
  26. 26.
    Iversen LE (2010) Consideration of the cathinones. Advisory Council on the Misuse of Drugs. A report submitted to the Home Secretary of the UK (March 31, 2010)Google Scholar
  27. 27.
    Meltzer PC, Butler D, Deschamps JR, et al. (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49:1420–1432CrossRefGoogle Scholar
  28. 28.
    Aarde SM, Creehan KM, Vandewater SA, et al. (2015) In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats. Psychopharmacology (Berl) 232:3045–3055CrossRefGoogle Scholar
  29. 29.
    Aarde SM, Huang PK, Creehan KM, et al. (2013) The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology 71:130–140CrossRefGoogle Scholar
  30. 30.
    Baumann MH, Partilla JS, Lehner KR, et al. (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 38:552–562CrossRefGoogle Scholar
  31. 31.
    Fantegrossi WE, Gannon BM, Zimmerman SM, et al. (2013) In vivo effects of abused ‘bath salt’ constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology 38:563–573CrossRefGoogle Scholar
  32. 32.
    Gatch MB, Dolan SB, Forster MJ (2015) Comparative behavioral pharmacology of three pyrrolidine-containing synthetic cathinone derivatives. J Pharmacol Exp Ther 354:103–110CrossRefGoogle Scholar
  33. 33.
    Marusich JA, Antonazzo KR, Wiley JL, et al. (2014) Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87:206–213CrossRefGoogle Scholar
  34. 34.
    Marusich JA, Grant KR, Blough BE, et al. (2012) Effects of synthetic cathinones contained in “bath salts” on motor behavior and a functional observational battery in mice. Neurotoxicology 33:1305–1313CrossRefGoogle Scholar
  35. 35.
    Watterson LR, Olive MF (2014) Synthetic cathinones and their rewarding and reinforcing effects in rodents. Adv Neurosci 2014:209875CrossRefGoogle Scholar
  36. 36.
    Watterson LR, Kufahl PR, Nemirovsky NE, et al. (2014) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol 19:165–174CrossRefGoogle Scholar
  37. 37.
    Gatch MB, Taylor CM, Forster MJ (2013) Locomotor stimulant and discriminative stimulus effects of ‘bath salt’ cathinones. Behav Pharmacol 24:437–447CrossRefGoogle Scholar
  38. 38.
    Cameron K, Kolanos R, Solis E, et al. (2013) Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J Pharmacol 168:1750–1757CrossRefGoogle Scholar
  39. 39.
    Cameron K, Kolanos R, Vekariya R, et al. (2013) Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of “bath salts,” produce opposite effects at the human dopamine transporter. Psychopharmacology (Berl) 227:493–499CrossRefGoogle Scholar
  40. 40.
    Kolanos R, Cameron KN, Vekariya RH et al (2011) “Bath salts”: an imitation of methamphetamine plus cocaine? Abstract #249. Southeast Regional American Chemical Society Meeting. Richmond, VAGoogle Scholar
  41. 41.
    Simmler LD, Buser TA, Donzelli M, et al. (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458–470CrossRefGoogle Scholar
  42. 42.
    Eshleman AJ, Wolfrum KM, Hatfield MG, et al. (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85:1803–1815CrossRefGoogle Scholar
  43. 43.
    Del Bello F, Sakloth F, Partilla JS, et al. (2015) Ethylenedioxy homologs of N-methyl-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) and its corresponding cathinone analog methylenedioxymethcathinone: interactions with transporters for serotonin, dopamine, and norepinephrine. Bioorg Med Chem 23:5574–5579CrossRefGoogle Scholar
  44. 44.
    Kolanos R, Solis Jr E, Sakloth F, et al. (2013) “deconstruction” of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter. ACS Chem Neurosci 4:1524–1529CrossRefGoogle Scholar
  45. 45.
    Kolanos R, Partilla JS, Baumann MH, et al. (2015) Stereoselective actions of methylenedioxypyrovalerone (MDPV) to inhibit dopamine and norepinephrine transporters and facilitate intracranial self-stimulation in rats. ACS Chem Neurosci 20:771–777CrossRefGoogle Scholar
  46. 46.
    Sakloth F, Kolanos R, Mosier PD, et al. (2015) Steric parameters, molecular modeling and hydropathic interaction analysis of the pharmacology of para-substituted methcathinone analogues. Br J Pharmacol 172:2210–2218CrossRefGoogle Scholar
  47. 47.
    Kolanos R, Sakloth F, Jain AD, et al. (2015) Structural modification of the designer stimulant α-pyrrolidinovalerophenone (α-PVP) influences potency at dopamine transporters. ACS Chem Neurosci 6:1726–1731CrossRefGoogle Scholar
  48. 48.
    Sakloth F (2015) Psychoactive synthetic cathinones (or ‘bath salts’): investigation of mechanisms of action. PhD dissertation, Virginia Commonwealth University, Richmond, VAGoogle Scholar
  49. 49.
    Bonano JS, Banks ML, Kolanos R, et al. (2015) Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues. Br J Pharmacol 172:2433–2444CrossRefGoogle Scholar
  50. 50.
    Gregg RA, Baumann MH, Partilla JS, et al. (2015) Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats. Br J Pharmacol 172:883–894CrossRefGoogle Scholar
  51. 51.
    Hutsell BA, Baumann MH, Partilla JS, et al. (2016) Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats. Eur Neuropsychopharmacol 26:288–297CrossRefGoogle Scholar
  52. 52.
    Suyama JA, Sakloth F, Kolanos R, et al. (2016) Abuse-related neurochemical effects of para-substituted methcathinone analogs in rats: microdialysis studies of nucleus accumbens dopamine and serotonin. J Pharmacol Exp Ther 356:182–190CrossRefGoogle Scholar
  53. 53.
    Negus SS, Mello NK, Blough BE, et al. (2007) Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate “agonist” medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther 320:627–636CrossRefGoogle Scholar
  54. 54.
    Saha K, Partilla JS, Lehner KR, et al. (2015) ‘Second-generation’ mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function. Neuropsychopharmacology 40:1321–1331CrossRefGoogle Scholar
  55. 55.
    Majchrzak M, Rojkiewicz M, Celiński R, et al. (2016) Identification and characterization of new designer drug 4-fluoro-PV9 and α-PHP in the seized materials. Forensic Toxicol 34:115–124CrossRefGoogle Scholar
  56. 56.
    Uchiyama N, Matsuda S, Kawamura M, et al. (2014) Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products. Forensic Sci Int 243:1–13CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 2.5 International License (, which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

Authors and Affiliations

  1. 1.Department of Medicinal Chemistry, School of PharmacyVirginia Commonwealth UniversityRichmondUSA

Personalised recommendations